AlzeCure signs collaboration, out-licensing deal with Lilly for Alzheimer's drug

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00

June 9 (Reuters) - AlzeCure Pharma ALZCUR.ST said on Tuesday it had entered a collaboration and out-licensing agreement with Eli Lilly LLY.N for the global rights of an Alzheimer's treatment in a deal that could exceed $1 billion in total value.

AlzeCure develops small-molecule drug candidates for central nervous system diseases with a focus on Alzheimer's disease and pain.

  • The deal is for the global rights to AlzeCure's drug candidate Alzstatin ACD680, currently in preclinical development

  • AlzeCure will receive an upfront payment of $10 million, development and commercial milestone payments, and tiered mid-single digit royalties on sales

  • Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid buildup in the brain and in the long term may be used to help prevent Alzheimer’s disease, CEO Martin Jönsson said


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.